- Study results have exciting therapeutic potential across wide range of CNS indications.
- VTGN focused on developing new generation of medications to treat anxiety, depression and more.
- Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression.
Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential.
“These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS (central nervous system) indications,” said VistaGen CEO Shawn Singh. “The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination.”
VistaGen is assessing the potential of the AV-101/probenecid combination as a treatment for multiple CNS disorders, including dyskinesia (unwanted movement) associated with levodopa therapy for Parkinson’s disease, epilepsy, major depressive disorder, neuropathic pain and suicidal ideation (thoughts and behaviors).The company’s efforts currently are focused on developing three new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates, AV-101, PH10 and PH94B, has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.
For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment